论文部分内容阅读
目的评价纳洛酮治疗肺性脑病的临床疗效及安全性,收集56例肺性脑病病例,比较在基础治疗相同的情况下,使用纳洛酮和未使用纳洛酮的异同。方法将56例肺性脑病随机分为治疗组及对照组,两组均予抗感染、解痉、u0001痰,保持气道通畅,持续低流量鼻导管吸氧,氧流量为1~3L/min,维持机体水、电解质平衡及营养支持等治疗。治疗组则加用纳洛酮注射剂治疗。结果治疗后,治疗组总有效率显著高于对照组(P<0.05);动脉血气分析指标:动脉血氧分压(PaO2)显著高于对照组(P<0.05)、动脉血二氧化碳分压(PaCO2)显著低于对照组(P<0.05);治疗过程中无不良反应发生。结论纳洛酮治疗肺性脑病临床疗效确切、安全性高。
Objective To evaluate the clinical efficacy and safety of naloxone in the treatment of pulmonary encephalopathy. Fifty-six cases of pulmonary encephalopathy were collected. The similarities and differences between naloxone and naloxone were compared under the same basic treatment. Methods 56 cases of pulmonary encephalopathy were randomly divided into treatment group and control group. Both groups were given anti-infective, antispasmodic and phlegm, maintained airway patency, continuous low-flow nasal catheter oxygen, oxygen flow was 1 ~ 3L / min, to maintain the body water, electrolyte balance and nutritional support and other treatment. The treatment group was treated with naloxone injection. Results After treatment, the total effective rate of the treatment group was significantly higher than that of the control group (P <0.05). Arterial blood gas analysis index: PaO2 was significantly higher than that of the control group (P <0.05), arterial partial pressure of carbon dioxide PaCO2) was significantly lower than the control group (P <0.05); no adverse reactions occurred during the treatment. Conclusion Naloxone treatment of pulmonary encephalopathy clinical curative effect is accurate and safe.